SCHEMBL990220

SCHEMBL990220

N#CCc1cccc(Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.39
IDH1 O75874 2/20 0.38
IDH2 P48735 2/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
KDM4E B2RXH2 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
LMNA P02545 1/20 0.34
IRAK4 Q9NWZ3 2/20 0.34
MBOAT4 Q96T53 1/20 0.33
TNF P01375 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
AGTR1 P30556 1/20 0.32
ENPP2 Q13822 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29705749 1.00 MAPT (0.43) MAPTMEN1KMT2AL3MBTL1IDH1
SCHEMBL1426671 0.84 MEN1 (0.50) MAPTMEN1KMT2AKDM4ETDP1
SCHEMBL2940122 0.79 MEN1 (0.43) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL29056051 0.75 MEN1 (0.43) MAPTMEN1KMT2AKDM4ETDP1
SCHEMBL1025377 0.75 IRAK4 (0.48) MAPTMEN1KMT2ACYP3A4KDM4E
SCHEMBL24890395 0.75 MEN1 (0.43) MAPTMEN1KMT2AKDM4ETDP1
SCHEMBL28889311 0.75 MEN1 (0.43) MAPTMEN1KMT2AKDM4ETDP1
SCHEMBL1249349 0.75 MEN1 (0.43) MAPTMEN1KMT2AKDM4ETDP1
SCHEMBL22071098 0.75 MEN1 (0.43) MAPTMEN1KMT2AKDM4ETDP1
SCHEMBL30395089 0.75 IRAK4 (0.48) MAPTMEN1KMT2ACYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 EP disclosed
WO-2025002177-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 长春金赛药业有限责任公司 2025-01-02 WO disclosed
CN-117986235-A P53-Y220C selective small molecule reactivation agent compound, pharmaceutical composition and application thereof 长春金赛药业有限责任公司 2024-05-07 CN disclosed
US-20230046018-A1 BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR QILU PHARMACEUTICAL CO., LTD. (CN) 2023-02-16 US disclosed
WO-2022253334-A1 CRYSTAL FORM OF RAF KINASE INHIBITOR AND PREPARATION METHOD THEREFOR 南京明德新药研发有限公司 2022-12-08 WO disclosed
CN-114555573-A Prostaglandin E2(PGE2)EP4Receptor antagonists 多曼治疗学公司 2022-05-27 CN disclosed
WO-2021110141-A1 BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR 南京明德新药研发有限公司 2021-06-10 WO disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
US-20160031812-A1 SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN SOLACE PHARMACEUTICALS UK LTD. (GB) 2016-02-04 US disclosed
CN-101400660-A Triazole derivative or salt thereof ASTELLAS PHARMA INC (JP) 2009-04-01 CN disclosed
US-20090082367-A1 TRIAZOLE DERIVATIVE OR A SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-03-26 US disclosed
EP-1995243-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 EP disclosed
WO-2004108722-A1 ORTHOCONDENSED POLYCYCLIC AMINOPYRROLE DERIVATIVES COMPRISING AN ELECTRO-ATTRACTIVE SUBSTITUENT, COMBINATION PRODUCTS OF SAID DERIVATIVES, AND METHOD FOR THE PRODUCTION THEREOF PIERRE FABRE UROLOGIE (FR) 2004-12-16 WO disclosed
WO-2001017965-A2 CYANOPIPERIDINES AS PESTICIDES SYNGENTA PARTICIPATIONS AG (CH) 2001-03-15 WO disclosed
US-5677329-A ANTAGONIST TO EPIDERMAL GROWTH FACTOR RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1997-10-14 US disclosed
US-5597837-A Method and composition for treating psoriasis with styryl-substituted pyridyl compounds Rh one-Poulenc Rorer Pharmaceuticals Inc. (US) 1997-01-28 US disclosed
EP-0525109-A4 STYRYL-SUBSTITUTED MONOCYCLIC AND BICYCLIC HETEROARYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE 1993-06-30 EP disclosed
EP-0525109-A1 STYRYL-SUBSTITUTED MONOCYCLIC AND BICYCLIC HETEROARYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1993-02-03 EP disclosed
US-4369322-A WITH CYANOGEN CHLORIDE DEGUSSA AG (DE) 1983-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031812-A1 SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN SPR, QDPR, SRR MAPT 2193/4885MEN1 4856/4885KMT2A 3756/4885
US-20230046018-A1 BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR BRAF, RAF1, ARAF MAPT 3593/4885MEN1 2574/4885KMT2A 751/4885
US-20160159773-A1 HETEROCYCLIC COMPOUND TYK2, SSB, UACA MAPT 277/4885MEN1 1167/4885KMT2A 281/4885
US-20090082367-A1 TRIAZOLE DERIVATIVE OR A SALT THEREOF HSD11B1, HSD11B2, HSD17B1 MAPT 3869/4885MEN1 2335/4885KMT2A 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.